Novavax (NASDAQ: NVAX) reported Q2 EPS of ($4.75), $1.12 worse than the analyst estimate of ($3.63). Revenue for the quarter came in at $298 million versus the consensus estimate of $387.87 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.

Earnings

Novavax (NVAX) and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 VaAugust 5, 2021 4:06 PM Novavax (NVAX) Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary VaccinationAugust 5, 2021 4:06 PM Novavax Reports Second Quarter 2021 Financial Results and Operational HighlightsAugust 5, 2021 4:05 PM EU seals deal with Novavax for up to 200 million COVID-19 vaccinesAugust 4, 2021 9:30 AM Novavax (NVAX), European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 VaccineAugust 4, 2021 9:10 AM European Commission approves new contract for a potential COVID-19 vaccine with Novavax (NVAX) August 4, 2021 9:10 AM